Given the importance of neoangiogenesis in SCLC and the correlation between decreased survival and a higher serum concentration of VEGF, the combination of immunotherapy and antiangiogenic agents is under investigation on the premise that the vascular normalization, which may result from antiangiogenesis, will lead to better T-cell infiltration in tumors and less hypoxia and will, therefore, synergize with checkpoint inhibitors. Here, VEGFA is linked to small cell lung carcinoma.